ranolazine
Generic: ranolazine
Labeler: ncs healthcare of ky, llc dba vangard labsDrug Facts
Product Profile
Brand Name
ranolazine
Generic Name
ranolazine
Labeler
ncs healthcare of ky, llc dba vangard labs
Dosage Form
TABLET, EXTENDED RELEASE
Routes
Active Ingredients
ranolazine 500 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
0615-8611
Product ID
0615-8611_1a937beb-d2a1-4ea1-8e06-e0c87b357168
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA210188
Listing Expiration
2027-12-31
Marketing Start
2019-09-10
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
06158611
Hyphenated Format
0615-8611
Supplemental Identifiers
RxCUI
UNII
NUI
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
ranolazine (source: ndc)
Generic Name
ranolazine (source: ndc)
Application Number
ANDA210188 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 500 mg/1
Packaging
- 30 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0615-8611-39)
Packages (1)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "1a937beb-d2a1-4ea1-8e06-e0c87b357168", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "unii": ["A6IEZ5M406"], "rxcui": ["616749"], "spl_set_id": ["2373687b-b9a4-496e-b89f-9754f8513fd3"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["NCS HealthCare of KY, LLC dba Vangard Labs"]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0615-8611-39)", "package_ndc": "0615-8611-39", "marketing_start_date": "20260114"}], "brand_name": "Ranolazine", "product_id": "0615-8611_1a937beb-d2a1-4ea1-8e06-e0c87b357168", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "0615-8611", "generic_name": "Ranolazine", "labeler_name": "NCS HealthCare of KY, LLC dba Vangard Labs", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Ranolazine", "active_ingredients": [{"name": "RANOLAZINE", "strength": "500 mg/1"}], "application_number": "ANDA210188", "marketing_category": "ANDA", "marketing_start_date": "20190910", "listing_expiration_date": "20271231"}